Compare SHMD & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SHMD | CRVS |
|---|---|---|
| Founded | 1864 | 2014 |
| Country | Germany | United States |
| Employees | 676 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 301.4M | 1.2B |
| IPO Year | N/A | 2016 |
| Metric | SHMD | CRVS |
|---|---|---|
| Price | $6.97 | $12.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.17 |
| AVG Volume (30 Days) | 1.2M | ★ 1.7M |
| Earning Date | 05-15-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 48.04 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.00 | $3.38 |
| 52 Week High | $10.65 | $26.95 |
| Indicator | SHMD | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 57.30 | 36.24 |
| Support Level | $5.29 | $6.65 |
| Resistance Level | $7.19 | $19.21 |
| Average True Range (ATR) | 0.67 | 1.04 |
| MACD | 0.17 | -0.44 |
| Stochastic Oscillator | 64.15 | 13.81 |
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.